<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22799" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatoblastoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Musick</surname>
            <given-names>Sierra R.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Melinda</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rouster</surname>
            <given-names>Audra S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sierra Musick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Melinda Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Audra Rouster declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22799.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hepatoblastomas are the most common primary malignant liver tumor in pediatric patients, and most often occur within the first 2 years of life. The histologic types are subdivided into the epithelial type and the mixed type. Over the last 3 decades, the treatment has advanced, and neoadjuvant chemotherapy is now the standard of care for most cases. Neoadjuvant chemotherapy and surgical resection produce a cure rate of approximately 70 percent, a vast improvement over the dismal 30 percent cure rate in the 1970s. Prognosis is based on many factors including alpha-fetoprotein levels, age at the time of diagnosis, completeness of resection, and clinical stage of the disease. This activity describes the evaluation and management of hepatoblastomas and highlights the role of the interprofessional team in improving care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>State the epidemiology of hepatoblastomas.</p></list-item><list-item><p>Explain treatment considerations for patients with hepatoblastomas.</p></list-item><list-item><p>Describe the presentation of a patient with a hepatoblastoma.</p></list-item><list-item><p>Employ interprofessional team strategies for improving coordination and communication to advance the care of patients with hepatoblastomas and optimize outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22799&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22799">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22799.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hepatoblastomas are the most common primary malignant liver tumor in pediatric patients, occurring mostly within the first 2 years of life.<xref ref-type="bibr" rid="article-22799.r1">[1]</xref>&#x000a0;The&#x000a0;histologic types are subdivided into 2 broad categories: epithelial type and mixed type. Over the last 3 decades, the treatment has advanced with neo-adjuvant chemotherapy now the standard of care for most cases. Neo-adjuvant chemotherapy and surgical resection produce a cure rate of approximately 70%, a vast improvement over the dismal 30% cure rate in the 1970s. Prognosis is based on many factors including alpha-fetoprotein levels, age at the time of diagnosis, completeness of resection, and clinical stage of the disease.<xref ref-type="bibr" rid="article-22799.r2">[2]</xref></p>
      </sec>
      <sec id="article-22799.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Most tumors are sporadic, but one-third of cases may be&#x000a0;associated with Beckwith-Weidemann, familial adenomatous polyposis (FAP), Edward syndrome (trisomy 18), nephroblastoma, and Down syndrome.<xref ref-type="bibr" rid="article-22799.r3">[3]</xref>&#x000a0;Low birth weight infants are at higher risk of developing a hepatoblastoma and evidence has shown an association with preeclampsia and parental tobacco smoking before and during pregnancy.<xref ref-type="bibr" rid="article-22799.r3">[3]</xref><xref ref-type="bibr" rid="article-22799.r4">[4]</xref>&#x000a0;Other factors thought to play a role in pathogenesis include oxygen therapy, certain medication (furosemide), radiation, plasticizers, and total parenteral nutrition (TPN).<xref ref-type="bibr" rid="article-22799.r2">[2]</xref></p>
        <p>The most common genetic mutation involves the Wnt signaling pathway which results in the accumulation of beta-catenin; these mutations are present in a higher proportion of the sporadic cases.<xref ref-type="bibr" rid="article-22799.r5">[5]</xref>&#x000a0;By immunohistochemistry, beta-catenin usually shows a membranous staining pattern in the more differentiated fetal types and nuclear staining pattern in the less differentiated histologic types.<xref ref-type="bibr" rid="article-22799.r6">[6]</xref>&#x000a0;In aggressive cases, activation of TERT (human telomerase reverse transcriptase) and MYC signaling has been&#x000a0;shown<xref ref-type="bibr" rid="article-22799.r2">[2]</xref></p>
      </sec>
      <sec id="article-22799.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hepatoblastoma is a rare tumor comprising approximately 1% of all pediatric tumors.<xref ref-type="bibr" rid="article-22799.r7">[7]</xref>&#x000a0;The incidence rate is slowly increasing in North America and Europe, and there is a slight male predominance.<xref ref-type="bibr" rid="article-22799.r8">[8]</xref></p>
      </sec>
      <sec id="article-22799.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Hepatoblastomas originate from primitive hepatic stem cells that give rise to the epithelial components of the liver. Classically, these tumors are&#x000a0;divided into 2 broad categories: epithelial type (E-HB) and mixed epithelial and mesenchymal type (MEM-HB). Revision of this original classification system resulted in the pathology consensus of the pediatric hepatoblastoma classification system, which&#x000a0;retained the subdivision of&#x000a0;the histologic types into 2 broad categories, as described above. The&#x000a0;E-HB includes fetal, pleomorphic, embryonal, macrotrabecular, small cell undifferentiated (SCU), cholangioblastic and mixed epithelial variants. The MEM-HB is subdivided into tumors with teratoid features and tumors without teratoid features.</p>
        <p>The fetal subtype is further stratified into 4 categories: well-differentiated; crowded or mitotically active; pleomorphic, poorly differentiated; and anaplastic. The well-differentiated variant is characterized by a low power view demonstrating alternating light and dark areas due to variable cytoplasmic glycogen content. Assessment at higher power reveals a uniform population of hepatocytes arranged in trabeculae that are 2 to 3 cells thick. Extramedullary hematopoiesis is a typical finding, and mitotic rate&#x000a0;is low. Description of the other&#x000a0;variants&#x000a0;is beyond the scope of&#x000a0;this article.</p>
        <p>The embryonal subtype is the most commonly encountered subtype and consists of basophilic cells with scant cytoplasm and increased mitotic rate that is&#x000a0;arranged in nests, trabeculae, acini, pseudorosettes, or sheets. The macrotrabecular subtype is arranged in trabeculae that&#x000a0;are more than ten cells thick. The SCU subtype consists of dyscohesive, uniform round cells arranged in sheets with increased mitotic activity. Some cases of SCU have a loss of INI1, suggesting a possible association with primary rhabdoid tumors of the liver. The cholangioblastic variant has bile ducts, typically located&#x000a0;at the periphery of epithelial sheets.</p>
        <p>The MEM-HB comprises 20-30% of tumors and contains a variable combination of epithelial and mesenchymal components. Most commonly, the epithelial component is fetal or embryonal, and the mesenchymal component is osteoid. Stromal derivatives include spindle cells, osteoid, skeletal muscle, and cartilage.&#x000a0;Teratoid features include primitive endoderm, neural derivatives, melanin, squamous and glandular elements.<xref ref-type="bibr" rid="article-22799.r2">[2]</xref><xref ref-type="bibr" rid="article-22799.r9">[9]</xref></p>
      </sec>
      <sec id="article-22799.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Hepatoblastomas usually present with as a single, mildly painful, rapidly enlarging abdominal mass that arises in the right lobe of the liver in 55% to 60% of cases.<xref ref-type="bibr" rid="article-22799.r10">[10]</xref>&#x000a0;Rapid enlargement of&#x000a0;these&#x000a0;tumors rarely results in tumor rupture&#x000a0;and hemorrhage. Tumors may reach up to 25 cm in size. Most tumors are solitary; however, up to 15% of tumors are multifocal. Some cases are associated with non-specific symptoms such as weight loss, failure to thrive or anorexia.<xref ref-type="bibr" rid="article-22799.r7">[7]</xref>&#x000a0;Significant elevations of&#x000a0;alpha-fetoprotein&#x000a0;(AFP) are observed in 90% of patients, and rarely, a paraneoplastic syndrome can occur.</p>
      </sec>
      <sec id="article-22799.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Ultrasound (US) and either computed tomography (CT) or magnetic resonance imaging (MRI) are the imaging modalities used to define the extent of tumor involvement of the liver and aid in pre-surgical planning. A chest CT can help detect lung metastasis;&#x000a0;the lung is the most common location of metastases and up to 20% of cases present with metastases.<xref ref-type="bibr" rid="article-22799.r7">[7]</xref>&#x000a0;After imaging, a biopsy, alpha-fetoprotein level, liver function tests, and a hepatitis panel&#x000a0;are performed as needed. Consent for participation in biologic studies should be&#x000a0;requested&#x000a0;before the biopsy is performed so the specimen can be properly allocated and handled.<xref ref-type="bibr" rid="article-22799.r9">[9]</xref></p>
      </sec>
      <sec id="article-22799.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Surgical resection is the mainstay of treatment with resectability of the tumor determining the need for neo-adjuvant or adjuvant chemotherapy. At presentation, approximately 60% of tumors are unresectable.<xref ref-type="bibr" rid="article-22799.r11">[11]</xref>&#x000a0;If unresectable and chemotherapy fails to shrink the tumor to a resectable size, a liver transplant can be done and has a good long-term survival rate.<xref ref-type="bibr" rid="article-22799.r12">[12]</xref>&#x000a0;The benefit of radiation therapy is unclear, with some unresectable cases responding well. Alpha-fetoprotein levels&#x000a0;are useful for tracking surgical success and whether the tumor has metastasized.<xref ref-type="bibr" rid="article-22799.r10">[10]</xref>&#x000a0;An increased risk of post-transplant lymphoproliferative disorder after&#x000a0;immunosuppression for liver transplant has been suggested in some publications.<xref ref-type="bibr" rid="article-22799.r6">[6]</xref></p>
      </sec>
      <sec id="article-22799.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis includes hepatocellular carcinoma (HCC), focal nodular hyperplasia, hepatic adenoma, lymphoma, and metastases. HCC can appear similar to the macrotrabecular subtype of hepatoblastoma, however, usually affects an adult patient population with risk factors such as metabolic disorders, liver cirrhosis, or childhood hepatitis B infection. Focal nodular hyperplasia usually affects older children and adults. Hepatic adenoma can resemble pure fetal hepatoblastomas; however, these rarely occur in persons under 5 years of age unless they have an underlying metabolic disorder.</p>
      </sec>
      <sec id="article-22799.s10" sec-type="Staging">
        <title>Staging</title>
        <p>The Children&#x02019;s Hepatic Tumors International Collaboration (CHIC) constructed a staging and risk stratification system intended to standardize the assessment of this tumor across the globe. This new staging system is called the Children&#x02019;s Hepatic Tumors International Collaboration&#x000a0;&#x02013;&#x000a0;Hepatoblastoma Stratification and incorporates confirmed prognostic factors from prior risk stratification systems with new additional factors to stratify patients into 4 risk groups.</p>
        <p>Found to be most predictive are AFP levels, patient age, Pretreatment Extent of Disease (PRETEXT) group (I, II, III, or IV), the presence of&#x000a0;metastases, and PRETEXT annotation factor. PRETEXT group is based on the extent of the tumor in the liver. PRETEXT annotation factor is determined to be positive if at least 1 of the following 5 factors are present: involvement of the vena cava or all 3 hepatic veins, or both (V); involvement of portal bifurcation or both right and left portal veins, or both (P); extrahepatic contiguous tumor extension (E); multifocal liver tumor (F); tumor rupture at diagnosis (R). Gender, low birth weight, prematurity, and Beckwith-Wiedemann syndrome were not found to be significant. Of note, the histologic type was&#x000a0;not included in this risk stratification system but may be incorporated at a future date. Validation of these risk groups is in progress.<xref ref-type="bibr" rid="article-22799.r2">[2]</xref><xref ref-type="bibr" rid="article-22799.r13">[13]</xref></p>
      </sec>
      <sec id="article-22799.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis is based on numerous factors including age of diagnosis, PRETEXT group, metastases, alfa fetal protein (AFP) levels, histologic subtype, completeness of resection, and clinical stage of the disease.&#x000a0; With certainty, the well-differentiated fetal subtype is associated with a better prognosis compared with small cell undifferentiated and macrotrabecular, which are linked to unfavorable prognosis.<xref ref-type="bibr" rid="article-22799.r13">[13]</xref>&#x000a0;Of note, the histologic subtype&#x000a0;is only&#x000a0;prognostically valuable before treatment with chemotherapy.&#x000a0;Alfa-fetoprotein is typically high upon diagnosis, but a significant drop after neo-adjuvant chemotherapy portends a better response to treatment. Younger age of diagnosis has historically been a poor prognostic factor; however, recent studies have called this into question, providing evidence that&#x000a0;these younger patients do just as well as older children.<xref ref-type="bibr" rid="article-22799.r14">[14]</xref>&#x000a0; Specifically, children younger than 1 year of age have a&#x000a0;better prognosis and children greater than 6 years of age have a&#x000a0;worse prognosis.<xref ref-type="bibr" rid="article-22799.r2">[2]</xref>&#x000a0;Tumor presence at the resection&#x000a0;margin, multifocality, and metastases have been&#x000a0;shown to be&#x000a0;poor prognostic factors.&#x000a0;Beta-catenin&#x000a0;expression has been shown to be associated with a lower period of event-free survival, while EpCAM expression has been associated with higher tumor viability and a poorer response to neo-adjuvant chemotherapy.<xref ref-type="bibr" rid="article-22799.r15">[15]</xref><xref ref-type="bibr" rid="article-22799.r16">[16]</xref></p>
      </sec>
      <sec id="article-22799.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Intraperitoneal tumor rupture</p>
          </list-item>
          <list-item>
            <p>Complications related to chemotherapy</p>
          </list-item>
          <list-item>
            <p>Post-transplant complications</p>
          </list-item>
          <list-item>
            <p>Psychosocial effects of treatment and painful procedures</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22799.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Improved clinical outcomes are achieved when hepatoblastomas are managed by an interprofessional team which may&#x000a0;include a pediatrician, oncologist, radiologist, pediatric surgeon, hepatologist and a transplant specialist.<xref ref-type="bibr" rid="article-22799.r17">[17]</xref>&#x000a0;After surgical resection, these children are monitored&#x000a0;by intensive care unit (ICU) nurses, therapists, dietitians, and an intensivist.</p>
      </sec>
      <sec id="article-22799.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22799&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22799">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/hepatoblastoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22799">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22799/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22799">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22799.s15">
        <fig id="article-22799.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Hepatoblastoma Contributed by Melinda Smith MD, West Virginia University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HB-1aCT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22799.s16">
        <fig id="article-22799.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Hepatoblastoma Contributed by Melinda Smith, MD, West Virginia University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HB-1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22799.s17">
        <fig id="article-22799.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Hepatoblastoma Contributed by Melinda Smith, MD, West Virginia University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HB-2__CT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22799.s18">
        <fig id="article-22799.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Hepatoblastoma Contributed by Melinda Smith, MD, West Virginia University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HB-2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22799.s19">
        <fig id="article-22799.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Hepatoblastoma Contributed by Melinda Smith, MD, West Virginia University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HB-4__CT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22799.s20">
        <title>References</title>
        <ref id="article-22799.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Subbarao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hepatoblastoma.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-200</page-range>
            <pub-id pub-id-type="pmid">28126357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czauderna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lopez-Terrada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hiyama</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>H&#x000e4;berle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Malogolowkin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-28</page-range>
            <pub-id pub-id-type="pmid">24322718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finegold</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lopez-Terrada</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Washington</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Qualman</surname>
                <given-names>SJ</given-names>
              </name>
              <collab>College of American Pathologists</collab>
            </person-group>
            <article-title>Protocol for the examination of specimens from pediatric patients with hepatoblastoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>520</fpage>
            <page-range>520-9</page-range>
            <pub-id pub-id-type="pmid">17425379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heck</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cockburn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Case-control study of birth characteristics and the risk of hepatoblastoma.</article-title>
            <source>Cancer Epidemiol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-5</page-range>
            <pub-id pub-id-type="pmid">23558166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curia</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Zuckermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Lellis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Catalano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lattanzio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aceto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Veschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Piantelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mariani-Costantini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cetta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Battista</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.</article-title>
            <source>Mod Pathol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-14</page-range>
            <pub-id pub-id-type="pmid">17962810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heczey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Himes</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>e21</fpage>
            <page-range>e21-e23</page-range>
            <pub-id pub-id-type="pmid">28837514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hepatoblastoma with pure fetal epithelial differentiation in a 10-year-old boy: A rare case report and review of the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>97</volume>
            <issue>2</issue>
            <fpage>e9647</fpage>
            <pub-id pub-id-type="pmid">29480877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pateva</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Egler</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Stearns</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Hepatoblastoma in an 11-year-old: Case report and a review of the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>e5858</fpage>
            <pub-id pub-id-type="pmid">28079820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Terrada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alaggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de D&#x000e1;vila</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Czauderna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hiyama</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Katzenstein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leuschner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Malogolowkin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ranganathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fabr&#x000e8;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>Children's Oncology Group Liver Tumor Committee</collab>
            </person-group>
            <article-title>Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium.</article-title>
            <source>Mod Pathol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>472</fpage>
            <page-range>472-91</page-range>
            <pub-id pub-id-type="pmid">24008558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiyama</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pediatric hepatoblastoma: diagnosis and treatment.</article-title>
            <source>Transl Pediatr</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-9</page-range>
            <pub-id pub-id-type="pmid">26835349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Tiao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Ville de Goyet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Superina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">24362406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hishiki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Irie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nosaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kasahara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>e27383</fpage>
            <pub-id pub-id-type="pmid">30084209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Maibach</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hiyama</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>H&#x000e4;berle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rangaswami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Malogolowkin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Perilongo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>von Schweinitz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez-Terrada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Alaggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leuschner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hishiki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saraceno</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Derosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Czauderna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.</article-title>
            <source>Lancet Oncol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>122</fpage>
            <page-range>122-131</page-range>
            <pub-id pub-id-type="pmid">27884679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dall'Igna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brugieres</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Christin</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Maibach</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Casanova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alaggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Goyet</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Zsiros</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Czauderna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Branchereau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perilongo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">28921839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiruthiga</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Ramakrishna</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival.</article-title>
            <source>J Gastrointest Oncol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>326</fpage>
            <page-range>326-337</page-range>
            <pub-id pub-id-type="pmid">29755772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Jou</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma.</article-title>
            <source>J Biomed Sci</source>
            <year>2017</year>
            <month>Aug</month>
            <day>29</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">28851352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22799.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shanmugam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vij</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Narasimhan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kota</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Munirathnam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kelgeri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sundaram</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rela</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary management of hepatoblastoma in children: Experience from a developing country.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">27781375</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
